Cargando…

Comparison of the SARS-CoV-2 BD Veritor Nasal Antigen Test with Nasopharyngeal Reverse Transcription-PCR in Symptomatic Patients

This study evaluated the BD Veritor system for rapid detection of SARS-CoV-2, an immunochromatographic point-of-care test, by comparing it with a standard reverse transcription-PCR (RT-PCR) methodology using samples from symptomatic patients. Samples from 146 symptomatic and 2 asymptomatic patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Koga, Paula, Maluf, Maira, Nunes, Fabiane, Campos, Juliana, Gazarini, Lívia, Borghoff, Tatiane, Libanori, Glaís, Martino, Marinês
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9603274/
https://www.ncbi.nlm.nih.gov/pubmed/36036635
http://dx.doi.org/10.1128/spectrum.00190-22
_version_ 1784817509327699968
author Koga, Paula
Maluf, Maira
Nunes, Fabiane
Campos, Juliana
Gazarini, Lívia
Borghoff, Tatiane
Libanori, Glaís
Martino, Marinês
author_facet Koga, Paula
Maluf, Maira
Nunes, Fabiane
Campos, Juliana
Gazarini, Lívia
Borghoff, Tatiane
Libanori, Glaís
Martino, Marinês
author_sort Koga, Paula
collection PubMed
description This study evaluated the BD Veritor system for rapid detection of SARS-CoV-2, an immunochromatographic point-of-care test, by comparing it with a standard reverse transcription-PCR (RT-PCR) methodology using samples from symptomatic patients. Samples from 146 symptomatic and 2 asymptomatic patients between the 1st and the 40th day of infection were evaluated. The nasopharyngeal and/or oropharyngeal swabs were inserted in a tube containing 0.9% saline solution and stored at refrigerator temperature until the moment of use. The samples were first tested with the Xpert Xpress SARS-CoV-2 (GeneXpert) kit (RT-PCR method), and the cycle thresholds (C(T)s) for the E and N2 genes encoding the SARS-CoV-2 envelope and nucleoprotein, respectively, were established. Subsequently, the same samples were tested using the Veritor rapid test. We analyzed the C(T)s of the N2 gene, which is detected in both methodologies, and observed sensitivities of 100%, 98.8%, 89.6%, and 82.7% for the C(T)s of <25, <27, and <30 and all the C(T)s, respectively. The greatest sensitivity was observed when we performed the test on patients within 5 days of symptom onset. The BD Veritor system’s workflow is simple and fast, taking approximately 16 min from sample preparation to obtaining the test result. In addition to its satisfactory sensitivity, with results that correlate with those of the RT-PCR, the BD Veritor analyzer instrument reduces the subjectivity of unaided visual readings and consequent potential variation in result interpretation. Therefore, our results showed that the BD Veritor diagnostic test can provide a rapid and accurate diagnosis for SARS-CoV-2. IMPORTANCE This study provides important and useful information, especially for diagnostic laboratories, since the results show that the BD Veritor system can provide a fast and safe point-of-care antigen diagnostic test for rapid detection of COVID-19 that has high sensitivity, reproducibility, and accuracy.
format Online
Article
Text
id pubmed-9603274
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher American Society for Microbiology
record_format MEDLINE/PubMed
spelling pubmed-96032742022-10-27 Comparison of the SARS-CoV-2 BD Veritor Nasal Antigen Test with Nasopharyngeal Reverse Transcription-PCR in Symptomatic Patients Koga, Paula Maluf, Maira Nunes, Fabiane Campos, Juliana Gazarini, Lívia Borghoff, Tatiane Libanori, Glaís Martino, Marinês Microbiol Spectr Research Article This study evaluated the BD Veritor system for rapid detection of SARS-CoV-2, an immunochromatographic point-of-care test, by comparing it with a standard reverse transcription-PCR (RT-PCR) methodology using samples from symptomatic patients. Samples from 146 symptomatic and 2 asymptomatic patients between the 1st and the 40th day of infection were evaluated. The nasopharyngeal and/or oropharyngeal swabs were inserted in a tube containing 0.9% saline solution and stored at refrigerator temperature until the moment of use. The samples were first tested with the Xpert Xpress SARS-CoV-2 (GeneXpert) kit (RT-PCR method), and the cycle thresholds (C(T)s) for the E and N2 genes encoding the SARS-CoV-2 envelope and nucleoprotein, respectively, were established. Subsequently, the same samples were tested using the Veritor rapid test. We analyzed the C(T)s of the N2 gene, which is detected in both methodologies, and observed sensitivities of 100%, 98.8%, 89.6%, and 82.7% for the C(T)s of <25, <27, and <30 and all the C(T)s, respectively. The greatest sensitivity was observed when we performed the test on patients within 5 days of symptom onset. The BD Veritor system’s workflow is simple and fast, taking approximately 16 min from sample preparation to obtaining the test result. In addition to its satisfactory sensitivity, with results that correlate with those of the RT-PCR, the BD Veritor analyzer instrument reduces the subjectivity of unaided visual readings and consequent potential variation in result interpretation. Therefore, our results showed that the BD Veritor diagnostic test can provide a rapid and accurate diagnosis for SARS-CoV-2. IMPORTANCE This study provides important and useful information, especially for diagnostic laboratories, since the results show that the BD Veritor system can provide a fast and safe point-of-care antigen diagnostic test for rapid detection of COVID-19 that has high sensitivity, reproducibility, and accuracy. American Society for Microbiology 2022-08-29 /pmc/articles/PMC9603274/ /pubmed/36036635 http://dx.doi.org/10.1128/spectrum.00190-22 Text en Copyright © 2022 Koga et al. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research Article
Koga, Paula
Maluf, Maira
Nunes, Fabiane
Campos, Juliana
Gazarini, Lívia
Borghoff, Tatiane
Libanori, Glaís
Martino, Marinês
Comparison of the SARS-CoV-2 BD Veritor Nasal Antigen Test with Nasopharyngeal Reverse Transcription-PCR in Symptomatic Patients
title Comparison of the SARS-CoV-2 BD Veritor Nasal Antigen Test with Nasopharyngeal Reverse Transcription-PCR in Symptomatic Patients
title_full Comparison of the SARS-CoV-2 BD Veritor Nasal Antigen Test with Nasopharyngeal Reverse Transcription-PCR in Symptomatic Patients
title_fullStr Comparison of the SARS-CoV-2 BD Veritor Nasal Antigen Test with Nasopharyngeal Reverse Transcription-PCR in Symptomatic Patients
title_full_unstemmed Comparison of the SARS-CoV-2 BD Veritor Nasal Antigen Test with Nasopharyngeal Reverse Transcription-PCR in Symptomatic Patients
title_short Comparison of the SARS-CoV-2 BD Veritor Nasal Antigen Test with Nasopharyngeal Reverse Transcription-PCR in Symptomatic Patients
title_sort comparison of the sars-cov-2 bd veritor nasal antigen test with nasopharyngeal reverse transcription-pcr in symptomatic patients
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9603274/
https://www.ncbi.nlm.nih.gov/pubmed/36036635
http://dx.doi.org/10.1128/spectrum.00190-22
work_keys_str_mv AT kogapaula comparisonofthesarscov2bdveritornasalantigentestwithnasopharyngealreversetranscriptionpcrinsymptomaticpatients
AT malufmaira comparisonofthesarscov2bdveritornasalantigentestwithnasopharyngealreversetranscriptionpcrinsymptomaticpatients
AT nunesfabiane comparisonofthesarscov2bdveritornasalantigentestwithnasopharyngealreversetranscriptionpcrinsymptomaticpatients
AT camposjuliana comparisonofthesarscov2bdveritornasalantigentestwithnasopharyngealreversetranscriptionpcrinsymptomaticpatients
AT gazarinilivia comparisonofthesarscov2bdveritornasalantigentestwithnasopharyngealreversetranscriptionpcrinsymptomaticpatients
AT borghofftatiane comparisonofthesarscov2bdveritornasalantigentestwithnasopharyngealreversetranscriptionpcrinsymptomaticpatients
AT libanoriglais comparisonofthesarscov2bdveritornasalantigentestwithnasopharyngealreversetranscriptionpcrinsymptomaticpatients
AT martinomarines comparisonofthesarscov2bdveritornasalantigentestwithnasopharyngealreversetranscriptionpcrinsymptomaticpatients